Intigyne (Lactobacillus Gasseri Dsm 14869, Lactobacillus Rhamnosus Dsm 14870)

The two Lactobacillus strains colonise the vaginal epithelium and produce lactic acid, hydrogen peroxide and bacteriocins. These substances lower the vaginal pH and create an environment that suppresses pathogenic bacteria and yeasts, thereby promoting a stable and protective microbial community.

The specific dosing regimen for Intigyne is determined by the prescribing healthcare professional based on the individual’s condition, age and treatment goals. Patients should follow the prescriber’s instructions and not alter the dose without medical advice.

Safety data for Intigyne in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential use with their obstetrician or healthcare provider to weigh any possible risks and benefits.

To order Intigyne, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and import documentation.

Intigyne contains two well‑characterised strains, Lactobacillus gasseri DSM 14869 and Lactobacillus rhamnosus DSM 14870, which have documented ability to adhere to vaginal epithelium and produce antimicrobial metabolites. Compared with generic multi‑strain products, these strains are selected for their proven efficacy in clinical studies on bacterial vaginosis and yeast infection recurrence.

Intigyne should be stored at ambient temperature, ideally below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and avoid exposure to extreme heat or humidity to maintain bacterial viability.

Intigyne is administered intravaginally, typically as a capsule or tablet that is inserted into the vagina according to the prescriber’s instructions. The route allows direct delivery of the probiotic strains to the vaginal mucosa where they can colonise and exert their beneficial effects.

While rare, serious risks include systemic infection in immunocompromised individuals and severe allergic reactions such as anaphylaxis. Users should seek immediate medical attention if they experience fever, persistent pelvic pain, widespread rash, swelling of the face or throat, or any signs of a severe reaction.

Intigyne should be avoided by individuals with a known hypersensitivity to any Lactobacillus species, those who are severely immunocompromised without medical supervision, and anyone who has been advised by a healthcare professional not to use vaginal probiotics for specific medical reasons.